The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
Exosome-mediated delivery of Cas9 ribonucleoprotein complexes for tissue-specific gene therapy of liver diseases
Open accessAbstract
CRISPR-Cas9 gene editing has emerged as a powerful therapeutic technology, but the lack of safe and efficient in vivo delivery systems, especially for tissue-specific vectors, limits its broad clinical applications. Delivery of Cas9 ribonucleoprotein (RNP) owns competitive advantages over other options; however, the large size of RNPs exceeds the loading capacity of currently available delivery vectors. Here, we report a previously unidentified genome editing delivery system, named exosome RNP , in which Cas9 RNPs were loaded into purified exosomes isolated from hepatic stellate cells through electroporation. Exosome RNP facilitated effective cytosolic delivery of RNP in vitro while specifically accumulated in the liver tissue in vivo. Exosome RNP showed vigorous therapeutic potential in acute liver injury, chronic liver fibrosis, and hepatocellular carcinoma mouse models via targeting p53 up-regulated modulator of apoptosis ( PUMA ), cyclin E1 ( CcnE1 ), and K (lysine) acetyltransferase 5 ( KAT5 ), respectively. The developed exosome RNP provides a feasible platform for precise and tissue-specific gene therapies of liver diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The biology , function , and biomedical applications of exosomes
Kalluri, R., & LeBleu, V. S. (2020) · Science · doi:10.1126/science.aau6977 · Cited by 10,770
Engineering precision nanoparticles for drug delivery
Mitchell, M. J., Billingsley, M. M., Haley, R. M., Wechsler, M. E., Peppas, N. A., & Langer, R. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0090-8 · Cited by 7,933
Routes and mechanisms of extracellular vesicle uptake
Mulcahy, L. A., Pink, R. C., & Carter, D. R. F. (2014) · Journal of Extracellular Vesicles · doi:10.3402/jev.v3.24641 · Cited by 2,832
Extracellular vesicles as a next-generation drug delivery platform
Herrmann, I. K., Wood, M. J. A., & Fuhrmann, G. (2021) · Nature Nanotechnology · doi:10.1038/s41565-021-00931-2 · Cited by 1,948
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis
Gillmore, J. D., Gane, E., Taubel, J., Kao, J., Fontana, M., Maitland, M. L., Seitzer, J., O’Connell, D., Walsh, K. R., Wood, K., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107454 · Cited by 1,801 · cited 1×
“Because of its site-specific and multiplexing capability, CRISPR-Cas9–mediated somatic genome editing has shown great potential in treating various genetic disorders in animal models (2–4) and even in a recent phase 1 clinical trial for transthyretin amyloidosis (5).”
BackgroundGenetic landscape and biomarkers of hepatocellular carcinoma
Zucman-Rossi, J., Villanueva, A., Nault, J.-C., & Llovet, J. M. (2015) · Gastroenterology · doi:10.1053/j.gastro.2015.05.061 · Cited by 1,325
Extracellular vesicles as drug delivery systems: Why and how?
Elsharkasy, O. M., Nordin, J. Z., Hagey, D. W., de Jong, O. G., Schiffelers, R. M., Andaloussi, S. E., & Vader, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.004 · Cited by 1,197
The promise and challenge of therapeutic genome editing
Doudna, J. A. (2020) · Nature · doi:10.1038/s41586-020-1978-5 · Cited by 1,126
Targeting Strategies for Tissue-Specific Drug Delivery
Zhao, Z., Ukidve, A., Kim, J., & Mitragotri, S. (2020) · Cell · doi:10.1016/j.cell.2020.02.001 · Cited by 1,099
Liver sinusoidal endothelial cells: Physiology and role in liver diseases
Poisson, J., Lemoinne, S., Boulanger, C., Durand, F., Moreau, R., Valla, D., & Rautou, P.-E. (2017) · Journal of Hepatology · doi:10.1016/j.jhep.2016.07.009 · Cited by 1,047
Human hepatic stellate cell lines, LX-1 and LX-2: new tools for analysis of hepatic fibrosis
Xu, L., Hui, A. Y., Albanis, E., Arthur, M. J., O’Byrne, S. M., Blaner, W. S., Mukherjee, P., Friedman, S. L., & Eng, F. J. (2005) · Gut · doi:10.1136/gut.2004.042127 · Cited by 1,014
Delivery strategies of the CRISPR-Cas9 gene-editing system for therapeutic applications
Liu, C., Zhang, L., Liu, H., & Cheng, K. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.012 · Cited by 607
Costa Verdera, H., Gitz-Francois, J. J., Schiffelers, R. M., & Vader, P. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.019 · Cited by 554
Kim, S. M., Yang, Y., Oh, S. J., Hong, Y., Seo, M., & Jang, M. (2017) · Journal of Controlled Release · doi:10.1016/j.jconrel.2017.09.013 · Cited by 481
Cancer stem cells in hepatocellular carcinoma — from origin to clinical implications
Lee, T. K.-W., Guan, X.-Y., & Ma, S. (2022) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00508-3 · Cited by 460
Nanoparticle Delivery of CRISPR/Cas9 for Genome Editing
Duan, L., Ouyang, K., Xu, X., Xu, L., Wen, C., Zhou, X., Qin, Z., Xu, Z., Sun, W., & Liang, Y. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.673286 · Cited by 377
Gee, P., Lung, M. S. Y., Okuzaki, Y., Sasakawa, N., Iguchi, T., Makita, Y., Hozumi, H., Miura, Y., Yang, L. F., Iwasaki, M., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-14957-y · Cited by 362
Dynamics of exosome internalization and trafficking
Tian, T., Zhu, Y., Hu, F., Wang, Y., Huang, N., & Xiao, Z. (2013) · Journal of Cellular Physiology · doi:10.1002/jcp.24304 · Cited by 340
Acetaminophen-related Hepatotoxicity
Bunchorntavakul, C., & Reddy, K. R. (2013) · Clinics in Liver Disease · doi:10.1016/j.cld.2013.07.005 · Cited by 322
Li, Z., Zhou, X., Wei, M., Gao, X., Zhao, L., Shi, R., Sun, W., Duan, Y., Yang, G., & Yuan, L. (2019) · Nano Letters · doi:10.1021/acs.nanolett.8b02689 · Cited by 318
Functional and genetic deconstruction of the cellular origin in liver cancer
Marquardt, J. U., Andersen, J. B., & Thorgeirsson, S. S. (2015) · Nature Reviews Cancer · doi:10.1038/nrc4017 · Cited by 306
The delivery challenge: fulfilling the promise of therapeutic genome editing
van Haasteren, J., Li, J., Scheideler, O. J., Murthy, N., & Schaffer, D. V. (2020) · Nature Biotechnology · doi:10.1038/s41587-020-0565-5 · Cited by 285
Morishita, M., Takahashi, Y., Nishikawa, M., Sano, K., Kato, K., Yamashita, T., Imai, T., Saji, H., & Takakura, Y. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24251 · Cited by 285
Extracellular vesicles in liver disease and potential as biomarkers and therapeutic targets
Szabo, G., & Momen-Heravi, F. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.71 · Cited by 285
Nakagawa, H., Maeda, S., Hikiba, Y., Ohmae, T., Shibata, W., Yanai, A., Sakamoto, K., Ogura, K., Noguchi, T., Karin, M., et al. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.07.006 · Cited by 250
The role of Kupffer cells in hepatic diseases
Li, P., He, K., Li, J., Liu, Z., & Gong, J. (2017) · Molecular Immunology · doi:10.1016/j.molimm.2017.02.018 · Cited by 233
Gupta, D., Liang, X., Pavlova, S., Wiklander, O. P. B., Corso, G., Zhao, Y., Saher, O., Bost, J., Zickler, A. M., Piffko, A., et al. (2020) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2020.1800222 · Cited by 214
Delivery of CRISPR/Cas systems for cancer gene therapy and immunotherapy
Song, X., Liu, C., Wang, N., Huang, H., He, S., Gong, C., & Wei, Y. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.04.010 · Cited by 212
In vivo delivery of CRISPR-Cas9 therapeutics: Progress and challenges
Behr, M., Zhou, J., Xu, B., & Zhang, H. (2021) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.05.020 · Cited by 210
Spatiotemporal control of CRISPR/Cas9 gene editing
Zhuo, C., Zhang, J., Lee, J.-H., Jiao, J., Cheng, D., Liu, L., Kim, H.-W., Tao, Y., & Li, M. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00645-w · Cited by 187
CRISPR Correction of Duchenne Muscular Dystrophy
Min, Y.-L., Bassel-Duby, R., & Olson, E. N. (2019) · Annual Review of Medicine · doi:10.1146/annurev-med-081117-010451 · Cited by 183
Ye, Y., Zhang, X., Xie, F., Xu, B., Xie, P., Yang, T., Shi, Q., Zhang, C.-Y., Zhang, Y., Chen, J., et al. (2020) · Biomaterials Science · doi:10.1039/d0bm00427h · Cited by 178
Cellular distribution of injected PLGA-nanoparticles in the liver
Park, J., Utsumi, T., Seo, Y.-E., Deng, Y., Satoh, A., Saltzman, W. M., & Iwakiri, Y. (2016) · Nanomedicine Nanotechnology Biology and Medicine · doi:10.1016/j.nano.2016.01.013 · Cited by 160
Simonsen, J. B. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1582237 · Cited by 156
Matsumoto, A., Takahashi, Y., Chang, H., Wu, Y.-W., Yamamoto, A., Ishihama, Y., & Takakura, Y. (2019) · Journal of Extracellular Vesicles · doi:10.1080/20013078.2019.1696517 · Cited by 148
Calvente, C. J., Sehgal, A., Popov, Y. V., Kim, Y. O., Zevallos, V. F., Şahin, U., Diken, M., & Schuppan, D. (2015) · Hepatology · doi:10.1002/hep.27936 · Cited by 138
Delivery of CRISPR/Cas9 for therapeutic genome editing
Xu, X., Wan, T., Xin, H., Li, D., Pan, H., Wu, J., & Ping, Y. (2019) · The Journal of Gene Medicine · doi:10.1002/jgm.3107 · Cited by 134
Self-citationThe Role of Sinusoidal Endothelial Cells in the Axis of Inflammation and Cancer Within the Liver
Wilkinson, A. L., Qurashi, M., & Shetty, S. (2020) · Frontiers in Physiology · doi:10.3389/fphys.2020.00990 · Cited by 121
CRISPR/Cas9: Principle, Applications, and Delivery through Extracellular Vesicles
Horodecka, K., & Düchler, M. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22116072 · Cited by 121
Wan, T. Y., Niu, D., Wu, C., Xu, F., Church, G. M., & Yuan, P. (2019) · Materials Today · doi:10.1016/j.mattod.2018.12.003 · Cited by 119
Self-citationHepatic Gene Transfer as a Means of Tolerance Induction to Transgene Products
LoDuca, P. A., Hoffman, B. E., & Herzog, R. W. (2009) · Current Gene Therapy · doi:10.2174/156652309787909490 · Cited by 118
Friend or Foe? Evidence Indicates Endogenous Exosomes Can Deliver Functional gRNA and Cas9 Protein
Chen, R., Huang, H., Liu, H., Xi, J., Ning, J., Zeng, W., Shen, C., Zhang, T., Yu, G., Xu, Q., et al. (2019) · Small · doi:10.1002/smll.201902686 · Cited by 114
Yan, X., Pan, Q., Xin, H., Chen, Y., & Yuan, P. (2021) · Science Advances · doi:10.1126/sciadv.abj0624 · Cited by 90
Self-citationChen, D., Ni, H., Wang, L., Ma, X., Yu, J., Ding, W., & Zhang, L. (2018) · Hepatology · doi:10.1002/hep.30422 · Cited by 87
A Versatile Nonviral Delivery System for Multiplex Gene‐Editing in the Liver
Gong, J., Wang, H., Lao, Y., Hu, H., Vatan, N. M., Guo, J., Ho, T., Huang, D., Li, M., Shao, D., et al. (2020) · Advanced Materials · doi:10.1002/adma.202003537 · Cited by 84
Kwan, S., Sheel, A., Song, C., Zhang, X., Jiang, T., Dang, H. T., Cao, Y., Özata, D. M., Mou, H., Yin, H., et al. (2019) · Hepatology · doi:10.1002/hep.30807 · Cited by 78
Advanced Nanotheranostics of CRISPR/Cas for Viral Hepatitis and Hepatocellular Carcinoma
Kong, H., Ju, E., Yi, K., Xu, W., Lao, Y., Cheng, D., Zhang, Q., Tao, Y., Li, M., & Ding, J. (2021) · Advanced Science · doi:10.1002/advs.202102051 · Cited by 78
Delivering on the promise of gene editing for cystic fibrosis
Hodges, C. A., & Conlon, R. A. (2018) · Genes & Diseases · doi:10.1016/j.gendis.2018.11.005 · Cited by 63
Nevzorova, Y. A., Bangen, J., Hu, W., Haas, U., Weiskirchen, R., Gaßler, N., Huss, S., Tacke, F., Siciński, P., Trautwein, C., et al. (2012) · Hepatology · doi:10.1002/hep.25736 · Cited by 61
Targeting CCl4‐induced liver fibrosis by RNA interference–mediated inhibition of cyclin E1 in mice
Bangen, J., Hammerich, L., Sonntag, R., Baues, M., Haas, U., Lambertz, D., Longerich, T., Lammers, T., Tacke, F., Trautwein, C., et al. (2017) · Hepatology · doi:10.1002/hep.29275 · Cited by 60
Delivery of genome-editing biomacromolecules for treatment of lung genetic disorders
Wan, T. Y., & Yuan, P. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.05.002 · Cited by 56
Self-citationActivation of Necroptosis by Engineered Self Tumor-Derived Exosomes Loaded with CRISPR/Cas9
Gulei, D., & Berindan‐Neagoe, I. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.05.032 · Cited by 51
New therapies for hepatic fibrosis
Koyama, Y., & Brenner, D. A. (2015) · Clinics and Research in Hepatology and Gastroenterology · doi:10.1016/j.clinre.2015.06.011 · Cited by 38
Gene editing technology as an approach to the treatment of liver diseases
Aravalli, R. N., & Steer, C. J. (2016) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2016.1158808 · Cited by 23
CRISPR/Cas9 therapeutics for liver diseases
Aravalli, R. N., & Steer, C. J. (2017) · Journal of Cellular Biochemistry · doi:10.1002/jcb.26627 · Cited by 19
A relaxin-based nanotherapy for liver fibrosis
Fallowfield, J. A., & Ramachandran, P. (2021) · Nature Nanotechnology · doi:10.1038/s41565-020-00832-w · Cited by 13
The State of the Art of Investigational and Approved Nanomedicine Products for Nucleic Acid Delivery
Paredes, K. O., Ruíz-Cabello, J., Alarcón, D. I., & Filice, M. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814470-1.00015-0 · Cited by 11
Cited by
CRISPR/Cas9 therapeutics: progress and prospects
Li, T., Yang, Y., Qi, H., Cui, W., Zhang, L., Fu, X., He, X., Liu, M., Li, P.-F., & Yu, T. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01309-7 · Cited by 719
Current Strategies for Exosome Cargo Loading and Targeting Delivery
Zeng, H., Guo, S., Ren, X., Wu, Z., Liu, S., & Yao, X. (2023) · Cells · doi:10.3390/cells12101416 · Cited by 424
Xu, G., Jin, J., Fu, Z., Wang, G., Lei, X., Xu, J., & Wang, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02312-w · Cited by 269
Engineered Exosome for Drug Delivery: Recent Development and Clinical Applications
Tian, J., Han, Z., Song, D., Peng, Y., Xiong, M., Chen, Z., Duan, S., & Zhang, L. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s444582 · Cited by 246
Current advances in non‐viral gene delivery systems: Liposomes versus extracellular vesicles
Belhadj, Z., Qie, Y., Carney, R. P., Li, Y., & Nie, G. (2023) · BMEMat · doi:10.1002/bmm2.12018 · Cited by 79
Metadata
- Authors
- Wan, T., Zhong, J., Pan, Q., Zhou, T., Ping, Y., & Liu, X.
- Venue
- Science Advances
- Published
- 2022-09-16
- Volume
- 8
- Issue
- 37
- Pages
- eabp9435-eabp9435
- ISSN
- 2375-2548 (ISSN-L)
- OpenAlex
- W4295706100
- Cited by
- 299
- References
- 57
- FWCI
- 16.50
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.